Early oncology focus Almac Discovery specializes in oncology, including first-in-class and best-in-class programs, presenting opportunities to partner on early-stage therapeutic concepts and novel targets in cancer research.

Clinical development access Though a small team, Almac Discovery leverages the broader Almac Group’s clinical development capabilities, enabling joint opportunities to advance lead candidates like ALM201 toward clinical milestones.

Strategic collaborations The company emphasizes collaboration with industrial and academic partners to translate research from concept to therapeutic, indicating openness to co-development, licensing, or sponsored research engagements.

Global capabilities With access to Almac Group facilities and expertise, there is potential to offer end-to-end services—from discovery through development and analytical testing—creating a compelling value proposition for external partners seeking turnkey solutions.

Emerging tech & validation Active research areas such as ubiquitin specific proteases and protein drug conjugates, combined with recent certifications and partnerships (e.g., CSP status with Olink), suggest opportunities to propose biomarker-driven studies and diagnostic collaborations to de-risk programs.